Cargando…
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
BACKGROUND: This first-in-human, phase I clinical trial of p28 (NSC745104), a 28-amino-acid fragment of the cupredoxin azurin, investigated the safety, tolerability, pharmacokinetics and preliminary activity of p28 in patients with p53(+) metastatic solid tumours. METHODS: A total of 15 patients wer...
Autores principales: | Warso, M A, Richards, J M, Mehta, D, Christov, K, Schaeffer, C, Rae Bressler, L, Yamada, T, Majumdar, D, Kennedy, S A, Beattie, C W, Das Gupta, T K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619084/ https://www.ncbi.nlm.nih.gov/pubmed/23449360 http://dx.doi.org/10.1038/bjc.2013.74 |
Ejemplares similares
-
p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013) -
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2()
por: Dickens, Michael P., et al.
Publicado: (2013) -
The Expression and Function of NUMB in Endometrial Cancer and the Interaction with HDM2 and P53
por: Wang, Chao, et al.
Publicado: (2015) -
Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.
por: Mehta, R. R., et al.
Publicado: (1995) -
Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction
por: Plante, Jeffrey P., et al.
Publicado: (2009)